Two stocks have drawn attention after directors made multimillion-dollar insider purchases. At CG Oncology, board member Brian Guan-Chyun Liu bought 371,085 shares for about $24.8 million on June 25, as the company advances its bladder cancer drug cretostimogene toward a Biologics License Application submission in the fourth quarter of 2026. JPMorgan analyst Brian Cheng rates the stock Overweight with a $96 price target, implying 35% upside, while the broader analyst consensus is a Strong Buy with an average target of $91.55. At Adobe, director David Ricks purchased 10,000 shares for nearly $1.95 million on the same day, bringing his total stake to roughly $4.5 million, even as the stock has fallen 37% year-to-date amid a CEO transition, a shift to a freemium model, and AI disruption concerns. Adobe reported record fiscal second-quarter revenue of $6.62 billion, up 13% year-over-year, and raised its full-year guidance, with Bernstein analyst Mark Moerdler maintaining an Outperform rating and a $379 price target that suggests 72% upside. The consensus rating on Adobe is a Hold, with an average price target of $260.11, indicating 18% upside from the current price of $219.72.
CG Oncology, Inc. Common stockBladder cancer drug advancing toward BLA submission in Q4 2026.
Adobe Inc.Director insider buying and raised full-year guidance signal confidence.